Bioasis Technologies Inc. V.BTI

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

TSXV:BTI - Post by User

Bioasis Technologies Inc. > The SMOKING Gun!!!

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 16, 2022 6:40pm

97 Views

Post# 35177052

RE:RE:The SMOKING Gun!!!

"So I read it a bit differently. So I think they are saying they are transitioning away from THEIR drug delivery strategy (Q-Sphera) to "development of therapeutics for rare diseases" which includes "Bioasis' enabling drug delivery platforms"."

Q-Sphera is important and a world first has been achieved with J&J. Extended release can be very important.

"We continue to believe there is substantial value to be unlocked from Midatech's MTX110, particularly in our ongoing phase I clinical trial in GBM, and to leverage our Q-Sphera technology." news release

News release: "On 17 June 2021 the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. The Company believes no other commercial or academic organisation has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling."

KayakerBC wrote:
A little further down, they state.....

"By combining the two groups to create Biodexa Pharmaceuticals, we have the opportunity to reposition the enlarged group as an emerging biotech company focused on the development of therapeutics for rare diseases, supported by Midatech and Bioasis' enabling drug delivery platforms....In combination with Bioasis' promising development pipeline we have the opportunity to create a much stronger group and transition from a drug delivery platform-based company to a therapeutics company."

So I read it a bit differently. So I think they are saying they are transitioning away from THEIR drug delivery strategy (Q-Sphera) to "development of therapeutics for rare diseases" which includes "Bioasis' enabling drug delivery platforms".